Alembic Pharmaceuticals on Monday said it has received approval from the US health regulator to market a generic medication used to treat moderate-to-severe psoriasis of the scalp.
The company has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Betamethasone Valerate Foam, the drug firm said in a statement.
The approved ANDA is therapeutically equivalent to the reference listed drug product Luxiq Foam (0.12 per cent), of Norvium Bioscience, LLC (Norvium).
Betamethasone valerate foam is a topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.
